Today's News, June 19, 2013

2:02a
AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza(R) (saxagliptin)   (Business Wire)

Yesterday's News, June 18, 2013

9:00a
Bristol-Myers Squibb Grants Help K-12 Educators Bring Science to Life and Help Students Explore Their Interests in the Sciences and Science-Based Careers   (Business Wire)
8:55a
Insider Trading Investment for Bank of America, Hewlett-Packard, Bristol Myers Squibb, Annaly Capital Management, Walt Disney, and American Capital Agency   (PR NewsWire)

June 17, 2013

8:00a
Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals   (PR NewsWire)

June 15, 2013

11:45a
Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma   (Business Wire)

June 14, 2013

9:00a
AstraZeneca and Bristol-Myers Squibb to Present New Data at American Diabetes Association 73rd Scientific Sessions(R)   (Business Wire)
8:00a
Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China   (Business Wire)
8:00a
Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China   (PR NewsWire)

June 12, 2013

1:11p
AstraZeneca and Bristol-Myers Squibb Statement on Proposal by the American Diabetes Association for Independent Review of Incretin-Based Therapies   (Business Wire)

June 11, 2013

6:05p
ORENCIA® (abatacept) Shows Comparable Efficacy to Humira® (adalimumab) in Year Two Data from Head-to-Head Study in Patients with Moderate to Severe Rheumatoid Arthritis   (PR NewsWire)
6:05p
ORENCIA(R) (abatacept) Shows Comparable Efficacy to Humira(R) (adalimumab) in Year Two Data from Head-to-Head Study in Patients with Moderate to Severe Rheumatoid Arthritis   (Business Wire)

June 10, 2013

3:46p
Ex-Bristol-Myers executive admits to insider trade   (MarketWatch)
1:40p
Priority Review for Gilead Drug - Analyst Blog   (Zacks.com)

June 7, 2013

8:30a
Insider Trading News for Gilead Sciences, Bristol Myers Squibb, Home Depot, EMC, Lowe's, and Juniper   (PR NewsWire)

June 6, 2013

5:10p
Priority Review for AZN/BMY Drug - Analyst Blog   (Zacks.com)

June 5, 2013

4:40p
Encouraging data from Bristol-Myers - Analyst Blog   (Zacks.com)
4:10p
The Medicines Co. Inks Deal with ProFibrix - Analyst Blog   (Zacks.com)
2:30p
Bristol-Myers Squibb to Take Part in Goldman Sachs Global Healthcare Conference   (Business Wire)

June 4, 2013

9:00p
Incyte Reveals Data on Oncology Candidate - Analyst Blog   (Zacks.com)
9:31a
Critical Alerts For Facebook, Bristol-Myers Squibb, Biogen Idec, Allstate, and AGCO Released By InvestorsObserver   (PR NewsWire)
9:03a
U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca's Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystrophy   (Business Wire)
9:00a
Earning Forecast for Intel, Microsoft, Merck, Citigroup, Bristol Myers Squibb, and JPMorgan Chase   (PR NewsWire)

June 3, 2013

6:38p
UPDATE 1: GM rises after hours on planned reentry to S&P 500   (MarketWatch)
4:46p
UPDATE 8: U.S. stocks make late leap in Fed-inspired trade   (MarketWatch)
4:30p
UPDATE 7: U.S. stocks make late leap in Fed-inspired trade   (MarketWatch)
3:49p
UPDATE 6: U.S. stocks mostly up in Fed-inspired trade   (MarketWatch)
2:58p
UPDATE 5: U.S. stocks mixed after weak factory data   (MarketWatch)
2:00p
Data on Merck Candidate at ASCO - Analyst Blog   (Zacks.com)
1:50p
UPDATE 4: U.S. stocks mainly lower on weak data; Dow gains   (MarketWatch)
1:38p
UPDATE 4: Monday's movers: Apple jitters pressure Pandora   (MarketWatch)
11:59a
UPDATE 3: Monday's movers: Pandora sinks on Apple worries   (MarketWatch)
11:53a
UPDATE 2: Monday's movers: Pandora sinks on Apple worries   (MarketWatch)

June 2, 2013

12:06p
Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy(R) (ipilimumab), in Patients with Advanced Melanoma   (Business Wire)

May 31, 2013

8:30a
Insider Trading for Federal National Mortgage Association, MEMC Electronic Materials, Applied Materials, Gilead Sciences, Newmont Mining, and Bristol-Myers Squibb   (PR NewsWire)

May 30, 2013

11:50p
NICE News for BMY/AstraZeneca - Analyst Blog   (Zacks.com)
Go to All Current & Historical News